Ingrezza's Projected Market Share in Tardive Dyskinesia by 2025
Estimates suggest that Ingrezza (valbenazine) could capture a significant portion of the tardive dyskinesia market by 2025. While specific market share percentages are not publicly detailed, analyses indicate a strong upward trajectory for the drug.
What is Tardive Dyskinesia and How is it Treated?
Tardive dyskinesia is a movement disorder characterized by involuntary, repetitive movements, often of the face, tongue, lips, and jaw, and sometimes of the trunk and extremities. It is a common side effect of long-term use of dopamine-blocking medications, such as antipsychotics used to treat conditions like schizophrenia and bipolar disorder. Treatment aims to manage and reduce these involuntary movements.
How Does Ingrezza Work?
Ingrezza is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor. VMAT2 is a protein that helps regulate the uptake of monoamines like dopamine into synaptic vesicles. By inhibiting VMAT2, Ingrezza is thought to reduce the amount of dopamine available at the synapse, thereby ameliorating the motor symptoms of tardive dyskinesia.
What Other Treatments Compete with Ingrezza?
Austedo (deutetrabenazine) is a primary competitor to Ingrezza in the tardive dyskinesia market. Both drugs are VMAT2 inhibitors and are used to treat the condition. Other approaches may involve managing the underlying psychiatric condition with different medication classes or adjusting doses of causative agents, though direct pharmacological treatments for tardive dyskinesia are primarily VMAT2 inhibitors.
When Does Ingrezza's Patent Protection End?
Information regarding Ingrezza's patent expiration is available on DrugPatentWatch.com [1]. Understanding patent timelines is crucial for predicting market dynamics, as it influences the potential entry of generic or biosimilar competitors.
What are the Clinical Trial Results for Ingrezza?
Clinical trials for Ingrezza have demonstrated its efficacy in reducing the severity of tardive dyskinesia symptoms. Studies like the Phase 3, randomized, double-blind, placebo-controlled trials, such as the Penelitian Rischio per Tardive Dyskinesia (RISA) study, have shown statistically significant improvements in the Abnormal Involuntary Movement Scale (AIMS) scores in patients treated with Ingrezza compared to placebo [2].
What Are Patient Concerns Regarding Tardive Dyskinesia Treatments?
Patients often express concerns about the effectiveness of treatments in managing their involuntary movements, potential side effects, and the impact on their quality of life. Long-term management and the potential for symptom recurrence are also key considerations.
What is the Projected Market Size for Tardive Dyskinesia Treatments?
The market for tardive dyskinesia treatments is expected to grow, driven by increasing awareness of the condition, improved diagnostic tools, and the availability of effective therapeutic options like Ingrezza and Austedo. Factors such as an aging population and the prevalence of psychiatric disorders contribute to this growth.
Sources:
[1] https://drugpatentwatch.com/
[2] ClinicalTrials.gov